This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Axcella Health Past Earnings Performance

Past criteria checks 0/6

Axcella Health's earnings have been declining at an average annual rate of -9.8%, while the Biotechs industry saw earnings growing at 17.4% annually.

Key information

-9.8%

Earnings growth rate

46.5%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth raten/a
Return on equityn/a
Net Marginn/a
Last Earnings Update30 Jun 2023

Recent past performance updates

Recent updates

Axcella Therapeutics drops 9% on $34.2M stock offering

Oct 13

Axcella adds 20% as mid-stage trial indicates potential of NASH therapy

Sep 29

Axcella Health GAAP EPS of -$0.40 misses by $0.02

Aug 12

Axcella Health: Revisiting A Lottery Ticket

Apr 25

Axcella Health EPS beats by $0.01

May 06

Have Insiders Been Buying Axcella Health Inc. (NASDAQ:AXLA) Shares This Year?

Feb 19
Have Insiders Been Buying Axcella Health Inc. (NASDAQ:AXLA) Shares This Year?

Axcella decides not to expand enrollment in AXA4010-001 following cohort 1 readout

Jan 11

Is Axcella Health Inc.'s (NASDAQ:AXLA) Shareholder Ownership Skewed Towards Insiders?

Dec 28
Is Axcella Health Inc.'s (NASDAQ:AXLA) Shareholder Ownership Skewed Towards Insiders?

Revenue & Expenses Breakdown

How Axcella Health makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:AXLA Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 230-481229
31 Mar 230-661345
31 Dec 220-811657
30 Sep 220-761756
30 Jun 220-741853
31 Mar 220-682046
31 Dec 210-651943
30 Sep 210-621841
30 Jun 210-591739
31 Mar 210-571737
31 Dec 200-571737
30 Sep 200-571639
30 Jun 200-621644
31 Mar 200-621644
31 Dec 190-591642
30 Sep 190-531437
30 Jun 190-451231
31 Mar 190-401028
31 Dec 180-36825

Quality Earnings: AXLA is currently unprofitable.

Growing Profit Margin: AXLA is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: AXLA is unprofitable, and losses have increased over the past 5 years at a rate of 9.8% per year.

Accelerating Growth: Unable to compare AXLA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AXLA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).


Return on Equity

High ROE: AXLA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/12/29 02:31
End of Day Share Price 2023/12/29 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Axcella Health Inc. is covered by 9 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mayank MamtaniB. Riley Securities, Inc.
Julian HarrisonBTIG
William FrohnhoeferBTIG